Lupin launches Sugammadex Injection in US after FDA approval
Lupin Limited launched Sugammadex Injection in the United States on July 31, 2026, following FDA approval. The product serves as a bioequivalent generic to Merck's Bridion, targeting the reversal of neuromuscular blockade in surgical settings. Available in 200 mg and 500 mg strengths, this launch enhances Lupin's complex generics offering in the lucrative US market.
*this image is generated using AI for illustrative purposes only.
Lupin Limited has launched Sugammadex Injection in the United States following approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA). The launch, announced on July 31, 2026, allows the Mumbai-headquartered pharmaceutical company to compete directly with Merck Sharp & Dohme LLC (Merck) in the market for reversal agents used during surgery. This move strengthens Lupin’s position in the high-margin complex generics segment by providing a cost-effective bioequivalent alternative to Merck’s branded product, Bridion®.
The FDA approved Lupin’s application based on bioequivalence to Bridion Injection, a registered trademark of Merck Sharp & Dohme B.V. Lupin is introducing the drug in two specific strengths, packaged as single-dose vials with a consistent concentration of 100 mg/mL. The product is indicated for the rapid reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in both adult patients and pediatric patients aged 2 years and older undergoing surgery.
Product Specifications
Lupin’s Sugammadex Injection is available in the following formulations:
| Strength | Volume | Concentration | Packaging |
|---|---|---|---|
| 200 mg | 2 mL | 100 mg/mL | Single-Dose Vial |
| 500 mg | 5 mL | 100 mg/mL | Single-Dose Vial |
Clinical Indication and Market Impact
Sugammadex is critical for patient safety, enabling faster emergence from anesthesia and reduced time in recovery rooms by quickly reversing muscle relaxation induced by blocking agents. By launching this generic version, Lupin aims to provide hospitals and surgical centers with a therapeutic equivalent that reduces costs compared to the branded option. The drug addresses a significant need in anesthesiology where precise control over neuromuscular blockade is essential.
This launch underscores Lupin’s strategic focus on differentiating its pipeline beyond commodity generics. Complex generics like neuromuscular blockers require rigorous bioequivalence studies and specialized manufacturing capabilities. The addition of Sugammadex to Lupin’s U.S. portfolio complements its existing presence in multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health.
Strategic Context
Lupin operates as a global pharmaceutical leader with products distributed in over 100 markets. The company supports its operations with 15 state-of-the-art manufacturing sites and 7 research centers globally, employing over 26,000 professionals. The launch aligns with Lupin’s broader ecosystem, which includes subsidiaries such as Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. By expanding its foothold in the U.S. market with high-value complex generics, Lupin aims to drive sustainable growth and improve patient health outcomes worldwide.
Historical Stock Returns for Lupin
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.01% | -2.16% | -11.16% | -0.79% | +13.48% | +137.62% |
How is Merck likely to adjust its pricing strategy for Bridion in response to Lupin's generic entry?
What impact will this launch have on Lupin's revenue mix and margins in the U.S. complex generics segment over the next two quarters?
Are there other complex generic candidates in Lupin's pipeline that could face similar competitive dynamics with branded incumbents in the near future?
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
